Demonstrate large animal efficacy, define protocols for the pivotal animal trial, and better understand the pharmacodynamics of TP508. To achieve this objective, we will conduct non-clinical…

Ended Definitive Contract Awarded Last action

Contract number
75A50119C00016
Awardee
Awarding agency
Obligated
$13,030,326

Award facts

Contract value 14% obligated
  • $13,030,325.84 Current, with exercised options
  • $94,847,914.84 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Basic Research
Pricing
Firm Fixed Price
Place of performance
Galveston, TX 77550, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00014 · DE-obligate remaining funds and closeout the contract in its entirety. -$11,857,903
Other Administrative Action P00013 · Chrysalis biotherapeutics - no cost extension for clin 0015 option 14. $0
Other Administrative Action P00012 · Chrysalis biotherapeutics - no cost extension for clin 0004 option 3. $0
Other Administrative Action P00011 · Chrysalis biotherapeutics - no cost extension for clin 0001 base period. $0
Other Administrative Action P00010 · Chrysalis biotherapeutics - no cost extension - clin 0009 option 8. $0
Funding Only Action P00009 · Chrysalis biotherapeutics - revise SOW option 18 and add supplemental funding. $3,000,000
Other Administrative Action P00008 · Chrysalis biotherapeutics - revise SOW option 3 and add hhsar clause 352.232-71, electronic submission of payment requests. $0
Change Order P00007 · Chrysalis biotherapeutics - advance the development of TP508 $0
Supplemental Agreement for work within scope P00006 · Advance the development of TP508 $0
Change Order P00005 · Chrysalis biotherapeutics - advance the development of TP508 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Exercise an Option P00002 $10,455,381
Supplemental Agreement for work within scope P00001 $1,358,755
Original award $10,074,093
Show all 15

About this award

Written by GovTribe AI ·

This is a $94,847,914.84 firm fixed-price definitive contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Chrysalis Biotherapeutics, Inc. The contract is for conducting non-clinical efficacy survival studies in male and female minipigs with the compound TP508, in order to demonstrate large animal efficacy, define protocols for the pivotal animal trial, and better understand the pharmacodynamics of TP508. The contract has no set-aside designation and is scheduled for completion by November 10, 2023. The contract is part of the TP508 major program.

Description

As the agency reported it.

Demonstrate large animal efficacy, define protocols for the pivotal animal trial, and better understand the pharmacodynamics of TP508. To achieve this objective, we will conduct non-clinical efficacy survival studies in male and female minipigs with

Quick answers

Who was awarded contract 75A50119C00016?

75A50119C00016 was awarded to Chrysalis Biotherapeutics, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 1, 2019.

How much is contract 75A50119C00016 worth?

The government has obligated $13,030,326 on 75A50119C00016. Its potential value, with all options, is $94,847,915.

Was contract 75A50119C00016 competed?

The extent of competition for 75A50119C00016 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login